GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Insider Ownership

Biogen (MEX:BIIB) Insider Ownership : 0.00 % (As of Jul. 21, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biogen's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biogen's Institutional Ownership is 68.49%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biogen's Float Percentage Of Total Shares Outstanding is 88.62%.


Biogen Insider Ownership Historical Data

The historical data trend for Biogen's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Insider Ownership Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biogen Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Biogen (MEX:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (MEX:BIIB) Headlines

From GuruFocus

Q2 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at Stifel CNS Days (Virtual) Transcript

By GuruFocus Research 01-22-2024

Biogen Inc Investor Day Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at SVB Leerink CNS Forum (Virtual) Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024